Heart failureRandomized controlled trialsDapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.doi:10.1038/s41591-019-0647-4Muthiah Vaduganathan...
在这段视频中,医学博士Javed Butler介绍了SGLT2抑制剂在心力衰竭中的应用系列。他讨论了心力衰竭的流行病学以及SGLT2抑制剂对心力衰竭结果的影响。医学博士Jonathan Rich将总结SGLT2抑制剂在心力衰竭患者专门试验中的效果。 Epidemiology of...
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multic...
[1] Vaduganathan M, et al., (2022). SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, doi: 10.1016/S0140-6736(22)01429-5. [2] Tuttle KR, e...
SGLT2 Inhibitors to Treat Heart Failure Activity Do It Better: Raising the Bar in Heart Failure Care With Practical Strategies for Treatment With SGLT2 Inhibitors Released:March 14, 2025 Expiration:March 13, 2026 Javed Butler, MD, MPH, MBA ...
SGLT-2 inhibitorsType 2 diabetescardiovascular outcomeheart failure hospitalizationHeart failure (HF) in type 2 diabetes mellitus (T2DM) poses a significant increase in mortality. Until recently, anti-diabetic drugs have not been shown to reduce hospitalization due to heart failure (hHF). While ...
[8] Packer M.(2020). Cardioprotective effects of Sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors, Circ Heart Fail, 13(9), e007197. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007197 [9] ...
该Meta分析包含5项相关研究（EMPEROR- PRESERVED、VERTIS-CV、DECLARE-TIMI 58、SOLOIST-WHF、SCORED）、9726例舒张性心衰患者，其中5046例接受SGLT2i治疗，4680例应用安慰剂。来源：[1]Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-...
9 Williams, D. M., Nawaz, A. & Evans, M. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Ther 12, 55-70, doi:10.1007/s13300-020-00951-6 (2021).10 Zinman, B. et al. Empagliflozin, ...
这一点变得至关重要,因为每组心力衰竭事件数量的相对较小变化可能会改变对试验结果的全面解释。 参考文献:FU Sheng, Litwin SE, Tedford RJ. Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies[J]. Nature Medicine,2021,27:1868-1875....